Qiagen received FDA 510(k) clearance for the QIAstat-DX Rise Syndromic Testing System, capable of processing up to 160 samples daily with automation features including cartridge loading/unloading and priority for urgent samples. This approval represents a significant enhancement for labs handling syndromic testing workloads, enabling expanded throughput and streamlined clinical workflows.